VistaGen Reports Positive New Data from Second Preclinical Study of AV-101 in Combination with Probenecid Sep 3, 2020
VistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Progress Aug 13, 2020
VistaGen Therapeutics Announces Exercise and Closing of Underwriters' Over-allotment Option in Underwritten Public Offering Aug 10, 2020
VistaGen Therapeutics Announces Receipt of $5 Million Non-Dilutive Upfront License Payment from EverInsight Therapeutics for PH94B Strategic Collaboration Aug 4, 2020
VistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public Offering of Common Stock Aug 2, 2020
VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety in Patients with Social Anxiety Disorder Jul 23, 2020
